

TABLE 158: GENOTYPE 1A TREATMENT-NAIVE WITH EMERGING TREATMENTS: RELATIVE RISKS AND RISK DIFFERENCE FOR ALL TREATMENT COMPARISONS — RANDOM EFFECTS MODEL

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
SOF24 + RBV24	PR48	2.18 (0.93 to 3.13)	44.50 (−2.89 to 65.56)
SIM12 + SOF12		2.29 (0.57 to 3.03)	49.85 (−15.83 to 64.96)
SOF12 + LDV12		2.59 (2.11 to 3.23)	59.42 (48.65 to 67.16)
SOF8 + LDV8 + RBV8		2.52 (1.82 to 3.16)	57.57 (32.61 to 65.97)
SOF12 + LDV12 + RBV12		2.63 (2.17 to 3.28)	60.82 (51.78 to 68.52)
SOF24 + LDV24 + RBV24		2.63 (2.16 to 3.28)	60.83 (51.53 to 68.38)
T12 PR24-48 RGT q8		1.80 (1.10 to 2.32)	29.94 (3.73 to 45.92)
T12 PR24-48 RGT q12		1.79 (0.81 to 2.45)	29.74 (−6.88 to 50.24)
T12 PR48 q8		2.16 (1.15 to 2.96)	44.05 (6.04 to 61.40)
SOF12 + PR12		1.84 (0.37 to 2.76)	31.77 (−23.38 to 58.75)
SIM12 PR24-48 RGT		1.86 (1.43 to 2.38)	31.91 (16.91 to 46.54)
SOF24 + RBV (low dose) 24		1.44 (0.26 to 2.84)	16.41 (−29.65 to 59.16)
PAR/RIT12 + OMB12 + DAS12 + RBV12		2.58 (2.07 to 3.24)	59.32 (45.60 to 67.40)
B24 PR28-48 RGT		1.63 (0.95 to 2.21)	23.72 (−1.74 to 43.22)
B44 PR48		1.94 (1.06 to 2.69)	35.57 (2.35 to 55.42)
GRZ12 + ELB12		2.40 (1.90 to 2.95)	52.47 (35.91 to 61.17)
DCV12 + ASU12 + BEC12 + RBV12		2.44 (1.55 to 3.09)	55.02 (20.83 to 65.50)
DCV12 + ASU12 + BEC12		2.25 (1.60 to 2.81)	47.21 (23.44 to 58.00)
GRZ12 + ELB12 (50 mg q.d.)		2.51 (1.73 to 3.24)	57.03 (29.66 to 67.92)
SIM12 + SOF12	SOF24 + RBV24	1.04 (0.27 to 2.36)	3.32 (−62.44 to 53.17)
SOF12 + LDV12		1.17 (0.97 to 2.62)	14.32 (−3.17 to 59.79)
SOF8 + LDV8 + RBV8		1.15 (0.83 to 2.55)	12.09 (−15.41 to 57.58)
SOF12 + LDV12 + RBV12		1.19 (1.00 to 2.67)	15.71 (−0.48 to 61.48)
SOF24 + LDV24 + RBV24		1.19 (0.99 to 2.64)	15.65 (−1.03 to 60.75)
T12 PR24-48 RGT q8		0.82 (0.49 to 1.87)	−14.61 (−46.66 to 33.67)
T12 PR24-48 RGT q12		0.82 (0.37 to 1.88)	−14.60 (−54.58 to 34.42)
T12 PR48 q8		0.99 (0.54 to 2.23)	−1.11 (−41.36 to 47.13)
SOF12 + PR12		0.86 (0.17 to 2.03)	−11.85 (−73.64 to 42.93)
SIM12 PR24-48 RGT		0.85 (0.59 to 1.96)	−12.27 (−38.45 to 36.75)
SOF24 + RBV (low dose) 24		0.67 (0.23 to 0.97)	−24.49 (−51.72 to −2.90)
PAR/RIT12 + OMB12 + DAS12 + RBV12		1.17 (0.95 to 2.61)	14.06 (−4.74 to 59.24)
B24 PR28-48 RGT		0.75 (0.42 to 1.75)	−20.53 (−52.09 to 29.67)
B44 PR48		0.89 (0.48 to 2.04)	−8.91 (−46.94 to 40.75)
GRZ12 + ELB12		1.09 (0.83 to 2.44)	7.32 (−15.63 to 53.22)
DCV12 + ASU12 + BEC12 + RBV12		1.11 (0.71 to 2.48)	9.15 (−26.44 to 55.62)
DCV12 + ASU12 + BEC12		1.02 (0.72 to 2.28)	1.91 (−26.03 to 48.15)
GRZ12 + ELB12 (50 mg q.d.)		1.13 (0.81 to 2.55)	11.01 (−17.09 to 57.66)
SOF12 + LDV12	SIM12 + SOF12	1.10 (0.97 to 4.42)	8.89 (−2.73 to 72.91)
SOF8 + LDV8 + RBV8		1.07 (0.87 to 4.18)	6.55 (−11.94 to 69.44)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
SOF12 + LDV12 + RBV12		1.12 (0.98 to 4.55)	10.47 (-1.96 to 75.92)
SOF24 + LDV24 + RBV24		1.12 (0.98 to 4.56)	10.40 (-2.35 to 75.29)
T12 PR24-48 RGT q8		0.79 (0.49 to 3.07)	-19.06 (-46.69 to 46.11)
T12 PR24-48 RGT q12		0.79 (0.38 to 3.02)	-18.73 (-55.01 to 45.70)
T12 PR48 q8		0.95 (0.56 to 3.62)	-4.87 (-40.48 to 58.75)
SOF12 + PR12		0.84 (0.26 to 1.87)	-13.35 (-57.40 to 27.07)
SIM12 PR24-48 RGT		0.81 (0.60 to 3.25)	-16.89 (-38.36 to 48.78)
SOF24 + RBV (low dose) 24		0.67 (0.12 to 2.70)	-26.92 (-80.74 to 45.71)
PAR/RIT12 + OMB12 + DAS12 + RBV12		1.10 (0.95 to 4.42)	8.76 (-4.55 to 73.22)
B24 PR28-48 RGT		0.72 (0.43 to 2.83)	-24.66 (-53.01 to 41.24)
B44 PR48		0.87 (0.48 to 3.40)	-12.00 (-47.57 to 54.01)
GRZ12 + ELB12		1.02 (0.83 to 4.14)	2.03 (-16.30 to 68.00)
DCV12 + ASU12 + BEC12 + RBV12		1.05 (0.70 to 4.20)	4.52 (-27.55 to 70.03)
DCV12 + ASU12 + BEC12		0.97 (0.72 to 3.75)	-2.69 (-26.56 to 60.55)
GRZ12 + ELB12 (50 mg q.d.)		1.07 (0.79 to 4.33)	6.43 (-20.41 to 71.71)
SOF8 + LDV8 + RBV8	SOF12 + LDV12	0.99 (0.77 to 1.02)	-1.43 (-20.71 to 2.02)
SOF12 + LDV12 + RBV12		1.01 (0.96 to 1.10)	1.31 (-3.57 to 8.61)
SOF24 + LDV24 + RBV24		1.01 (0.96 to 1.10)	1.33 (-4.06 to 8.54)
T12 PR24-48 RGT q8		0.70 (0.43 to 0.89)	-29.58 (-54.51 to -10.14)
T12 PR24-48 RGT q12		0.69 (0.32 to 0.93)	-29.72 (-64.44 to -6.48)
T12 PR48 q8		0.85 (0.49 to 0.99)	-14.97 (-48.69 to -1.21)
SOF12 + PR12		0.72 (0.15 to 0.96)	-27.31 (-80.19 to -3.47)
SIM12 PR24-48 RGT		0.72 (0.56 to 0.90)	-27.43 (-42.59 to -9.22)
SOF24 + RBV (low dose) 24		0.56 (0.11 to 0.97)	-42.68 (-86.17 to -2.87)
PAR/RIT12 + OMB12 + DAS12 + RBV12		1.00 (0.92 to 1.05)	0.03 (-7.53 to 4.29)
B24 PR28-48 RGT		0.63 (0.37 to 0.86)	-35.80 (-59.81 to -13.13)
B44 PR48		0.76 (0.42 to 0.96)	-23.46 (-55.46 to -3.52)
GRZ12 + ELB12		0.93 (0.77 to 1.04)	-6.76 (-21.86 to 3.35)
DCV12 + ASU12 + BEC12 + RBV12		0.96 (0.61 to 1.07)	-3.63 (-36.80 to 5.99)
DCV12 + ASU12 + BEC12		0.88 (0.65 to 1.00)	-12.08 (-33.92 to -0.44)
GRZ12 + ELB12 (50 mg q.d.)		0.98 (0.72 to 1.08)	-1.90 (-26.90 to 7.18)
SOF12 + LDV12 + RBV12	SOF8 + LDV8 + RBV8	1.03 (0.97 to 1.37)	2.79 (-2.53 to 25.75)
SOF24 + LDV24 + RBV24		1.03 (0.97 to 1.36)	2.77 (-3.00 to 25.47)
T12 PR24-48 RGT q8		0.71 (0.45 to 1.01)	-27.42 (-51.24 to 0.38)
T12 PR24-48 RGT q12		0.71 (0.34 to 1.03)	-27.48 (-60.80 to 2.13)
T12 PR48 q8		0.87 (0.51 to 1.10)	-12.52 (-45.83 to 7.66)
SOF12 + PR12		0.74 (0.16 to 1.00)	-24.38 (-77.91 to -0.35)
SIM12 PR24-48 RGT		0.73 (0.57 to 1.05)	-25.33 (-40.94 to 3.75)
SOF24 + RBV (low dose) 24		0.58 (0.11 to 1.05)	-39.83 (-84.41 to 3.76)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
PAR/RIT12 + OMB12 + DAS12 + RBV12		1.01 (0.94 to 1.29)	1.35 (-5.66 to 20.77)
B24 PR28-48 RGT		0.65 (0.39 to 0.96)	-33.57 (-57.33 to -2.73)
B44 PR48		0.78 (0.44 to 1.08)	-21.20 (-52.76 to 6.25)
GRZ12 + ELB12		0.95 (0.80 to 1.25)	-5.03 (-19.00 to 18.15)
DCV12 + ASU12 + BEC12 + RBV12		0.98 (0.64 to 1.27)	-1.92 (-33.68 to 19.53)
DCV12 + ASU12 + BEC12		0.89 (0.67 to 1.17)	-10.07 (-30.86 to 12.40)
GRZ12 + ELB12 (50 mg q.d.)		1.00 (0.74 to 1.31)	-0.40 (-24.93 to 22.78)
SOF24 + LDV24 + RBV24	SOF12 + LDV12 + RBV12	1.00 (0.94 to 1.06)	-0.04 (-5.82 to 5.28)
T12 PR24-48 RGT q8		0.69 (0.42 to 0.87)	-31.00 (-56.59 to -12.49)
T12 PR24-48 RGT q12		0.68 (0.31 to 0.91)	-31.19 (-66.30 to -8.39)
T12 PR48 q8		0.83 (0.47 to 0.98)	-16.43 (-51.82 to -2.36)
SOF12 + PR12		0.70 (0.14 to 0.97)	-28.97 (-83.40 to -3.29)
SIM12 PR24-48 RGT		0.71 (0.55 to 0.87)	-28.82 (-44.23 to -12.13)
SOF24 + RBV (low dose) 24		0.55 (0.11 to 0.95)	-44.16 (-87.80 to -4.74)
PAR/RIT12 + OMB12 + DAS12 + RBV12		0.99 (0.88 to 1.04)	-1.36 (-12.00 to 3.86)
B24 PR28-48 RGT		0.62 (0.36 to 0.84)	-37.23 (-61.88 to -15.16)
B44 PR48		0.75 (0.41 to 0.94)	-24.90 (-57.78 to -5.58)
GRZ12 + ELB12		0.92 (0.76 to 1.00)	-8.11 (-23.81 to 0.31)
DCV12 + ASU12 + BEC12 + RBV12		0.95 (0.60 to 1.03)	-5.05 (-39.16 to 3.07)
DCV12 + ASU12 + BEC12		0.86 (0.63 to 0.97)	-13.49 (-35.86 to -2.91)
GRZ12 + ELB12 (50 mg q.d.)		0.97 (0.71 to 1.04)	-3.37 (-28.26 to 3.99)
T12 PR24-48 RGT q8	SOF24 + LDV24 + RBV24	0.68 (0.42 to 0.87)	-30.98 (-56.70 to -12.29)
T12 PR24-48 RGT q12		0.68 (0.31 to 0.91)	-31.15 (-66.29 to -8.67)
T12 PR48 q8		0.83 (0.47 to 0.98)	-16.36 (-51.88 to -1.84)
SOF12 + PR12		0.71 (0.14 to 0.97)	-28.91 (-83.39 to -2.90)
SIM12 PR24-48 RGT		0.71 (0.55 to 0.87)	-28.83 (-44.30 to -11.92)
SOF24 + RBV (low dose) 24		0.55 (0.11 to 0.95)	-44.14 (-87.46 to -4.52)
PAR/RIT12 + OMB12 + DAS12 + RBV12		0.99 (0.88 to 1.05)	-1.35 (-12.11 to 4.24)
B24 PR28-48 RGT		0.62 (0.36 to 0.85)	-37.25 (-61.99 to -14.79)
B44 PR48		0.75 (0.41 to 0.94)	-24.85 (-57.21 to -5.49)
GRZ12 + ELB12		0.92 (0.76 to 1.00)	-8.12 (-23.80 to 0.39)
DCV12 + ASU12 + BEC12 + RBV12		0.95 (0.60 to 1.04)	-5.00 (-39.35 to 3.28)
DCV12 + ASU12 + BEC12		0.86 (0.63 to 0.97)	-13.42 (-36.09 to -2.76)
GRZ12 + ELB12 (50 mg q.d.)		0.97 (0.71 to 1.05)	-3.28 (-28.57 to 4.59)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
T12 PR24-48 RGT q12	T12 PR24-48 RGT q8	1.00 (0.60 to 1.31)	-0.25 (-23.60 to 17.08)
T12 PR48 q8		1.21 (0.65 to 1.96)	14.16 (-26.07 to 42.41)
SOF12 + PR12		1.03 (0.21 to 1.75)	1.93 (-56.23 to 36.51)
SIM12 PR24-48 RGT		1.03 (0.76 to 1.77)	1.89 (-19.07 to 32.50)
SOF24 + RBV (low dose) 24		0.81 (0.16 to 1.72)	-12.55 (-61.44 to 35.58)
PAR/RIT12 + OMB12 + DAS12 + RBV12		1.44 (1.10 to 2.32)	29.41 (8.54 to 54.27)
B24 PR28-48 RGT		0.91 (0.53 to 1.56)	-6.11 (-34.67 to 25.24)
B44 PR48		1.09 (0.59 to 1.84)	5.80 (-29.95 to 37.21)
GRZ12 + ELB12		1.33 (1.01 to 2.18)	22.43 (0.55 to 48.51)
DCV12 + ASU12 + BEC12 + RBV12		1.36 (0.85 to 2.19)	24.48 (-11.09 to 50.63)
DCV12 + ASU12 + BEC12		1.25 (0.87 to 2.00)	17.04 (-9.66 to 42.75)
GRZ12 + ELB12 (50 mg q.d.)		1.39 (0.96 to 2.30)	26.62 (-2.71 to 53.45)
T12 PR48 q8	T12 PR24-48 RGT q12	1.21 (0.64 to 2.56)	14.09 (-27.96 to 50.46)
SOF12 + PR12		1.03 (0.21 to 2.15)	2.14 (-57.99 to 42.59)
SIM12 PR24-48 RGT		1.03 (0.73 to 2.37)	2.09 (-22.22 to 42.69)
SOF24 + RBV (low dose) 24		0.82 (0.15 to 2.09)	-11.59 (-63.23 to 41.16)
PAR/RIT12 + OMB12 + DAS12 + RBV12		1.44 (1.06 to 3.12)	29.54 (5.03 to 64.43)
B24 PR28-48 RGT		0.91 (0.52 to 2.04)	-5.83 (-37.32 to 34.01)
B44 PR48		1.09 (0.59 to 2.39)	5.96 (-31.41 to 45.34)
GRZ12 + ELB12		1.33 (0.97 to 2.89)	22.57 (-2.51 to 57.82)
DCV12 + ASU12 + BEC12 + RBV12		1.36 (0.84 to 2.90)	24.52 (-12.42 to 60.20)
DCV12 + ASU12 + BEC12		1.26 (0.85 to 2.64)	17.15 (-11.84 to 51.94)
GRZ12 + ELB12 (50 mg q.d.)		1.39 (0.95 to 3.02)	26.66 (-4.26 to 62.85)
SOF12 + PR12	T12 PR48 q8	0.87 (0.18 to 1.53)	-10.85 (-68.86 to 27.76)
SIM12 PR24-48 RGT		0.85 (0.62 to 1.61)	-12.13 (-34.46 to 28.94)
SOF24 + RBV (low dose) 24		0.68 (0.13 to 1.54)	-25.35 (-75.60 to 28.73)
PAR/RIT12 + OMB12 + DAS12 + RBV12		1.18 (1.02 to 2.00)	14.79 (1.49 to 46.73)
B24 PR28-48 RGT		0.75 (0.44 to 1.44)	-20.15 (-48.48 to 21.59)
B44 PR48		0.91 (0.49 to 1.68)	-7.84 (-43.82 to 33.15)
GRZ12 + ELB12		1.10 (0.87 to 1.94)	7.96 (-11.39 to 43.99)
DCV12 + ASU12 + BEC12 + RBV12		1.12 (0.74 to 1.99)	10.13 (-22.42 to 46.12)
DCV12 + ASU12 + BEC12		1.03 (0.74 to 1.84)	2.72 (-22.43 to 39.24)
GRZ12 + ELB12 (50 mg q.d.)		1.15 (0.83 to 2.06)	12.10 (-14.78 to 48.74)
SIM12 PR24-48 RGT	SOF12 + PR12	1.00 (0.67 to 5.13)	0.08 (-30.04 to 58.00)
SOF24 + RBV (low dose) 24		0.82 (0.15 to 4.59)	-11.85 (-71.57 to 60.61)
PAR/RIT12 + OMB12 + DAS12 + RBV12		1.39 (1.03 to 6.75)	26.92 (2.76 to 80.83)
B24 PR28-48 RGT		0.89 (0.50 to 4.32)	-7.77 (-42.61 to 50.89)
B44 PR48		1.05 (0.57 to 4.99)	3.70 (-36.19 to 61.54)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
GRZ12 + ELB12		1.29 (0.91 to 6.45)	20.07 (-7.92 to 76.28)
DCV12 + ASU12 + BEC12 + RBV12		1.31 (0.80 to 6.39)	21.36 (-17.17 to 77.72)
DCV12 + ASU12 + BEC12		1.21 (0.80 to 5.94)	14.28 (-17.24 to 70.46)
GRZ12 + ELB12 (50 mg q.d.)		1.34 (0.90 to 6.73)	23.78 (-8.92 to 80.23)
SOF24 + RBV (low dose) 24	SIM12 PR24-48 RGT	0.78 (0.14 to 1.51)	-15.57 (-64.51 to 30.31)
PAR/RIT12 + OMB12 + DAS12 + RBV12		1.39 (1.09 to 1.79)	27.24 (7.09 to 42.68)
B24 PR28-48 RGT		0.88 (0.49 to 1.26)	-8.16 (-38.04 to 15.40)
B44 PR48		1.05 (0.56 to 1.49)	3.38 (-32.72 to 28.55)
GRZ12 + ELB12		1.29 (0.98 to 1.67)	20.32 (-1.42 to 36.72)
DCV12 + ASU12 + BEC12 + RBV12		1.32 (0.81 to 1.73)	22.60 (-14.05 to 40.28)
DCV12 + ASU12 + BEC12		1.22 (0.83 to 1.58)	15.05 (-13.35 to 32.58)
GRZ12 + ELB12 (50 mg q.d.)		1.35 (0.94 to 1.77)	24.55 (-4.83 to 42.48)
PAR/RIT12 + OMB12 + DAS12 + RBV12	SOF24 + RBV (low dose) 24	1.79 (1.02 to 9.24)	42.36 (2.13 to 86.07)
B24 PR28-48 RGT		1.12 (0.51 to 5.94)	6.54 (-41.42 to 57.48)
B44 PR48		1.32 (0.58 to 7.12)	17.27 (-34.65 to 69.13)
GRZ12 + ELB12		1.66 (0.92 to 8.53)	35.33 (-6.98 to 80.33)
DCV12 + ASU12 + BEC12 + RBV12		1.67 (0.84 to 8.58)	36.52 (-13.28 to 82.99)
DCV12 + ASU12 + BEC12		1.55 (0.82 to 8.06)	29.54 (-15.75 to 76.33)
GRZ12 + ELB12 (50 mg q.d.)		1.72 (0.93 to 8.86)	38.71 (-5.90 to 84.28)
B24 PR28-48 RGT	PAR/RIT12 + OMB12 + DAS12 + RBV12	0.63 (0.37 to 0.88)	-35.60 (-59.87 to -11.26)
B44 PR48		0.76 (0.42 to 0.98)	-23.27 (-55.33 to -2.01)
GRZ12 + ELB12		0.93 (0.77 to 1.07)	-6.66 (-21.50 to 6.00)
DCV12 + ASU12 + BEC12 + RBV12		0.96 (0.62 to 1.09)	-3.54 (-36.45 to 8.13)
DCV12 + ASU12 + BEC12		0.88 (0.65 to 1.02)	-11.89 (-33.76 to 1.41)
GRZ12 + ELB12 (50 mg q.d.)		0.98 (0.72 to 1.12)	-1.84 (-26.61 to 10.06)
B44 PR48	B24 PR28-48 RGT	1.19 (0.63 to 2.14)	11.63 (-25.54 to 43.27)
GRZ12 + ELB12		1.47 (1.05 to 2.47)	28.61 (3.36 to 53.49)
DCV12 + ASU12 + BEC12 + RBV12		1.49 (0.90 to 2.53)	30.54 (-6.78 to 56.23)
DCV12 + ASU12 + BEC12		1.38 (0.90 to 2.33)	23.28 (-7.09 to 48.52)
GRZ12 + ELB12 (50 mg q.d.)		1.53 (1.02 to 2.65)	32.63 (1.71 to 59.33)
GRZ12 + ELB12	B44 PR48	1.22 (0.92 to 2.21)	16.30 (-7.27 to 49.16)
DCV12 + ASU12 + BEC12 + RBV12		1.25 (0.77 to 2.23)	18.25 (-18.39 to 51.36)
DCV12 + ASU12 + BEC12		1.15 (0.80 to 2.06)	11.06 (-17.25 to 44.48)
GRZ12 + ELB12 (50 mg q.d.)		1.27 (0.89 to 2.34)	20.25 (-9.33 to 54.32)
DCV12 + ASU12 + BEC12 + RBV12	GRZ12 + ELB12	1.03 (0.66 to 1.25)	2.76 (-30.60 to 18.55)
DCV12 + ASU12 + BEC12		0.94 (0.69 to 1.15)	-5.07 (-27.83 to 11.31)

TREATMENT	REFERENCE	RR (95% CRI)	RD % (95% CRL)
GRZ12 + ELB12 (50 mg q.d.)		1.05 (0.77 to 1.28)	4.36 (-20.97 to 21.21)
DCV12 + ASU12 + BEC12	DCV12 + ASU12 + BEC12 + RBV12	0.92 (0.73 to 1.30)	-7.22 (-25.40 to 18.07)
GRZ12 + ELB12 (50 mg q.d.)		1.01 (0.76 to 1.60)	1.32 (-22.42 to 35.51)
GRZ12 + ELB12 (50 mg q.d.)	DCV12 + ASU12 + BEC12	1.11 (0.82 to 1.53)	9.25 (-16.10 to 33.08)
Random effect model	Residual deviance	45.62 vs. 46 data points	
	Deviance information criteria	254.423	
Fixed effect model	Residual deviance	46.9 vs. 46 data points	
	Deviance information criteria	254.213	

ASU = asunaprevir; B = boceprevir; BEC = beclabuvir; Crl = credible interval; DAS = dasabuvir; DCV = daclatasvir; ELB = elbasvir; GRZ = grazoprevir; LDV = ledipasvir; OMB = ombitasvir; PAR = paritaprevir; PR = pegylated interferon plus ribavirin; q8 = every 8 hours; q12 = every 12 hours; q.d. = once daily; RBV = ribavirin; RD = risk difference; RGT = response-guided therapy; RIT = ritonavir; RR = relative risk; SIM = simeprevir; SOF = sofosbuvir; T = telaprevir; vs. = versus.

Note: Please refer to Treatment Regimen Nomenclature table for description of dosages.